PFEWhy shares have fallen in previous years:
COVID Product Demand Crash: A sharp decline in sales of the Comirnaty vaccine and Paxlovid led to revenues falling from $100.3B in 2022 to $58.5B in 2023.
"Patent Cliff" Concerns: The impending loss of exclusivity (LOE) for blockbusters like Eliquis, Ibrance, and Xeljanz by 2028 threatened $17–18B in annual revenue.
Weakened Guidance: Management repeatedly revised revenue and earnings forecasts downwards
Improving Fundamentals
Financial Stabilization: Pfizer finally broke the revenue instability cycle, ending 2025 with a series of "dual beats" (beating both EPS and revenue expectations).
Cost Efficiency: The management successfully implemented a multi-billion dollar cost-saving program. Margins are expanding even with moderate sales growth.
Dividend Yield ~ 6.7%
Catalysts for Future Growth
🔎
🔎 Full Research :
🌐 t.me/A3MInvestments
🌐 t.me/A3MInvestments
Exención de responsabilidad
La información y las publicaciones no constituyen, ni deben considerarse como asesoramiento o recomendaciones financieras, de inversión, de trading o de otro tipo proporcionadas o respaldadas por TradingView. Más información en Condiciones de uso.
🔎 Full Research :
🌐 t.me/A3MInvestments
🌐 t.me/A3MInvestments
Exención de responsabilidad
La información y las publicaciones no constituyen, ni deben considerarse como asesoramiento o recomendaciones financieras, de inversión, de trading o de otro tipo proporcionadas o respaldadas por TradingView. Más información en Condiciones de uso.